Appointment of Joint Broker
November 01st, 2021
BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has appointed Panmure Gordon (UK) Limited to act as Joint Broker to the Company alongside SP Angel Corporate Finance LLP with immediate effect.
Related Stories
Head office
Copyright: BiVictriX Therapeutics plc 2023.
All Rights Reserved. Design & Development By Online Web Studio